Drug Profile
HBS 102
Alternative Names: CSTI-100; HBS-102Latest Information Update: 23 May 2022
Price :
$50
*
At a glance
- Originator ConSynance Therapeutics
- Developer ConSynance Therapeutics; Harmony Biosciences
- Class Hepatoprotectants; Neuroprotectants; Sleep disorder therapies
- Mechanism of Action MCHR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Narcolepsy
- Research Neurological disorders
- No development reported Non-alcoholic steatohepatitis